8 results on '"Legrand, V.M.G. (Victor)"'
Search Results
2. Meeting report ESC Forum on Drug Eluting Stents, European Heart House, Nice, 27-28 September 2007
- Author
-
Daemen, J. (Joost), Simoons, M.L. (Maarten), Wijns, W. (William), Bagust, A. (Adrian), Bos, G. (Gert), Bowen, J.M. (James), Braunwald, E. (Eugene), Camenzind, E. (Edoardo), Chevalier, B. (Bernard), DiMario, C. (Carlo), Fajadet, J. (Jean), Gitt, A.K. (Anselm), Guagliumi, G. (Giulio), Hillege, H.L. (Hans), James, S.K. (Stefan), Jüni, P. (Peter), Kastrati, A. (Adnan), Kloth, S. (Sabine), Kristensen, S.D. (Steen), Krucoff, M. (Mitchell), Legrand, V.M.G. (Victor), Pfisterer, M.E. (Matthias), Rothman, M. (Martin), Serruys, P.W.J.C. (Patrick), Silber, S. (Sigmund), Steg, P.G. (Philippe Gabriel), Tariah, I. (Ibrahim), Wallentin, L.C. (Lars), Windecker, S.W. (Stephan), Daemen, J. (Joost), Simoons, M.L. (Maarten), Wijns, W. (William), Bagust, A. (Adrian), Bos, G. (Gert), Bowen, J.M. (James), Braunwald, E. (Eugene), Camenzind, E. (Edoardo), Chevalier, B. (Bernard), DiMario, C. (Carlo), Fajadet, J. (Jean), Gitt, A.K. (Anselm), Guagliumi, G. (Giulio), Hillege, H.L. (Hans), James, S.K. (Stefan), Jüni, P. (Peter), Kastrati, A. (Adnan), Kloth, S. (Sabine), Kristensen, S.D. (Steen), Krucoff, M. (Mitchell), Legrand, V.M.G. (Victor), Pfisterer, M.E. (Matthias), Rothman, M. (Martin), Serruys, P.W.J.C. (Patrick), Silber, S. (Sigmund), Steg, P.G. (Philippe Gabriel), Tariah, I. (Ibrahim), Wallentin, L.C. (Lars), and Windecker, S.W. (Stephan)
- Published
- 2009
- Full Text
- View/download PDF
3. Diabetes does not influence treatment decisions regarding revascularization in patients with stable coronary artery disease
- Author
-
Breeman, A. (Arno), Boersma, H. (Eric), Bertrand, M.E. (Michel), Ottervanger, J.P. (Jan Paul), Hoeks, S.E. (Sanne), Lenzen, M.J. (Mattie), Sechtem, U. (Udo), Legrand, V.M.G. (Victor), Boer, M.J. (Menko Jan) de, Wijns, W. (William), Breeman, A. (Arno), Boersma, H. (Eric), Bertrand, M.E. (Michel), Ottervanger, J.P. (Jan Paul), Hoeks, S.E. (Sanne), Lenzen, M.J. (Mattie), Sechtem, U. (Udo), Legrand, V.M.G. (Victor), Boer, M.J. (Menko Jan) de, and Wijns, W. (William)
- Abstract
OBJECTIVE - To evaluate whether in stable angina preference for coronary revascularization by either percutaneous coronary intervention (PCI) or coronary artery bypass surgery (CABG) is influenced by diabetes status and whether this has prognostic implications. RESEARCH DESIGN AND METHODS - A total of 2,928 consecutive patients with stable angina who were enrolled in the prospective Euro Heart Survey on Coronary Revascularization were studied. Multivariable analyses were applied to evaluate the relation between diabetes, treatment decision, and 1-year outcome. RESULTS - Diabetes was documented in 587 patients (20%) who had more extensive coronary disease. Revascularization was intended in 74% of patients with diabetes and in 77% of those without diabetes. In patients selected for revascularization, CABG was intended in 35% of diabetic and in 33% of nondiabetic patients. Multivariable analyses did not change these findings, but in some subgroups diabetes influenced treatment decisions. For example, diabetic subjects with mild heart failure had more often intended revascularization (91%) than those without diabetes (67%, P < 0.001). Treatment decisions in patients with more extensive (left main, multivessel, or proximal left anterior descending artery) disease were not influenced by diabetes status. Diabetes was not associated with an increased incidence of all-cause death, nonfatal cerebrovascular accident, or nonfatal myocardial infarction at 1 year, regardless of preferred treatment. The incidence of the combined end points was 7.3% in diabetic and 6.8% in nondiabetic patients (adjusted hazard ratio 1.0 [95% CI 0.7-1.4]). CONCLUSIONS - In stable angina, treatment decisions regarding revascularization or the choice for CABG or PCI were not influenced by the presence of diabetes. Diabetes was not associated with a poor prognosis.
- Published
- 2006
- Full Text
- View/download PDF
4. Direct stenting with the Bx VELOCITY balloon-expandable stent mounted on the Raptor rapid exchange delivery system versus predilatation in a European randomized Trial: the VELVET trial.
- Author
-
Serruys, P.W.J.C. (Patrick), IJsselmuiden, S. (Sander), Hout, B.A. (Ben) van, Vermeersch, P. (Paul), Bramucci, E. (Ezio), Legrand, V.M.G. (Victor), Pieper, M. (Michael), Antoniucci, D. (David), Gomes, R.S. (Ricardo Seabra), Miguel, C.M. (Carlos), Boekstegers, P. (Peter), Lindeboom, W.K. (Wietze), Serruys, P.W.J.C. (Patrick), IJsselmuiden, S. (Sander), Hout, B.A. (Ben) van, Vermeersch, P. (Paul), Bramucci, E. (Ezio), Legrand, V.M.G. (Victor), Pieper, M. (Michael), Antoniucci, D. (David), Gomes, R.S. (Ricardo Seabra), Miguel, C.M. (Carlos), Boekstegers, P. (Peter), and Lindeboom, W.K. (Wietze)
- Abstract
AIMS: This study examined the six-month angiographic results of direct coronary stenting, and compared the nine-month safety, efficacy and cost of this strategy versus stenting after balloon predilatation. METHODS: In phase I of VELVET, 122 patients (mean age = 62.3 +/- 10.1 years, 77% male, 11% with diabetes) with angina pectoris or myocardial ischemia resulting from a single de novo 51% to 95% coronary stenosis underwent direct stenting. The endpoints of phase I included angiographic findings and rates of major adverse cardiac events up to six months of follow-up. In phase II, 401 patients (mean age = 61.3 +/- 10.8 years, 79% male, 16% with diabetes) with angina pectoris or documented myocardial ischemia resulting from single or multiple, de novo or restenotic, coronary lesions were randomized between direct
- Published
- 2003
- Full Text
- View/download PDF
5. Clinical and Economic Impact of Diabetes Mellitus on Percutaneous and Surgical Treatment of Multivessel Coronary Disease Patients
- Author
-
Sousa, J.E. (Eduardo), Costa, M.A. (Marco), Centemero, M., Abizaid, A.S. (Andrea), Legrand, V.M.G. (Victor), Limet, R.V. (Robert), Schuler, G. (Gerhard), Unger, F. (Felix), Mohr, F.W. (Friedrich), Lindeboom, W.K. (Wietze), Hugenholtz, P.G. (Paul), Sousa, A.G.M.R. (Amanda), Hout, B.A. (Ben) van, Serruys, P.W.J.C. (Patrick), Abizaid, A.C. (Alexandre), Sousa, J.E. (Eduardo), Costa, M.A. (Marco), Centemero, M., Abizaid, A.S. (Andrea), Legrand, V.M.G. (Victor), Limet, R.V. (Robert), Schuler, G. (Gerhard), Unger, F. (Felix), Mohr, F.W. (Friedrich), Lindeboom, W.K. (Wietze), Hugenholtz, P.G. (Paul), Sousa, A.G.M.R. (Amanda), Hout, B.A. (Ben) van, Serruys, P.W.J.C. (Patrick), and Abizaid, A.C. (Alexandre)
- Abstract
BACKGROUND: Our aims were to compare coronary artery bypass grafting (CABG) and stenting for the treatment of diabetic patients with multivessel coronary disease enrolled in the Arterial Revascularization Therapy Study (ARTS) trial and to determine the c
- Published
- 2001
- Full Text
- View/download PDF
6. Evolution of coronary atherosclerosis in patients with mild coronary artery disease studied by serial quantitative coronary angiography at 2 and 4 years follow up
- Author
-
Vos, J. (Jeroen), Feyter, P.J. (Pim) de, Kingma, J.H., Emanuelsson, H.U. (Hakan), Legrand, V.M.G. (Victor), Winkelmann, B., Dumont, J.M., Simoons, M.L. (Maarten), Vos, J. (Jeroen), Feyter, P.J. (Pim) de, Kingma, J.H., Emanuelsson, H.U. (Hakan), Legrand, V.M.G. (Victor), Winkelmann, B., Dumont, J.M., and Simoons, M.L. (Maarten)
- Abstract
AIMS: Angiographic studies on the natural course of both focal and diffuse coronary atherosclerosis have not been performed before, but can both be assessed by quantitative coronary angiography. The objective of this study was to describe the natural course of focal and diffuse coronary atherosclerosis over time. METHODS AND RESULTS: In 129 patients with mild coronary artery disease, but not on lipid-lowering medication, three coronary angiograms were made each 2 years apart. Nine hundred and sixty five angiographically diseased and non-diseased segments were analysed by quantitative coronary angiography. Mean lumen diameter and minimal lumen diameter were used as measures of diffuse and focal coronary atherosclerosis. Mean lumen diameter and minimum lumen diameter decreased by 0.02 and 0.03 mm per year. The rate of progression was similar in the angiographically non-diseased, as in the mildly and moderately diseased segments. Progression of diffuse coronary atherosclerosis was largest in severely stenosed lesions (percentage diameter stenosis > or = 50%) and in the right coronary artery with a loss of 0.19 mm and 0.16 mm in mean lumen diameter. Progression of focal disease was most prominent in new and mild lesions and the right coronary artery, with a decrease in minimum lumen diameter of 0.34 mm and 0.22 mm. In most subgroups, progression occurred gradually over time. On a per segment level, progression and the occurrence of new lesions occurred in 4.4% and 4.2%. Regression and disappearance of a lesions was found in 2.3% and 1.9%. On a per patient level, 36% were progressors, 12% had a mixed response, 36% were stable, and 16% were regressors. CONCLUSION: Diffuse and focal coronary atherosclerosis progressed at the same rate in the first and second 2 years in stenosed and non-stenosed segments. The rate of coronary atherosclerosis progression was small, but was higher for focal than for diffuse disease. A minority of lesions progressed and spontaneous regression
- Published
- 1997
7. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease
- Author
-
Serruys, P.W.J.C. (Patrick), Jaegere, P.P.T. (Peter) de, Kiemeneij, F. (Ferdinand), Miguel, C.M. (Carlos), Rutsch, W.R. (Wolfgang), Heyndrickx, G.R. (Guy), Emanuelsson, H.U. (Hakan), Marco, J. (Jean), Legrand, V.M.G. (Victor), Materne, P.H. (Phillipe), Belardi, J.A. (Jorge), Sigwart, U. (Ulrich), Colombo, A. (Antonio), Goy, J-J. (Jean-Jacques), Heuvel, P.A. (Paul) van den, Delcan, J., Morel, M-A.M. (Marie-Angèle), Serruys, P.W.J.C. (Patrick), Jaegere, P.P.T. (Peter) de, Kiemeneij, F. (Ferdinand), Miguel, C.M. (Carlos), Rutsch, W.R. (Wolfgang), Heyndrickx, G.R. (Guy), Emanuelsson, H.U. (Hakan), Marco, J. (Jean), Legrand, V.M.G. (Victor), Materne, P.H. (Phillipe), Belardi, J.A. (Jorge), Sigwart, U. (Ulrich), Colombo, A. (Antonio), Goy, J-J. (Jean-Jacques), Heuvel, P.A. (Paul) van den, Delcan, J., and Morel, M-A.M. (Marie-Angèle)
- Abstract
Balloon-expandable coronary-artery stents were developed to prevent coronary restenosis after coronary angioplasty. These devices hold coronary vessels open at sites that have been dilated. However, it is unknown whether stenting improves long-term angiographic and clinical outcomes as compared with standard balloon angioplasty.
- Published
- 1994
- Full Text
- View/download PDF
8. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease.
- Author
-
Serruys, P.W.J.C. (Patrick), Jaegere, P.P.T. (Peter) de, Kiemeneij, F. (Ferdinand), Miguel, C.M. (Carlos), Rutsch, W.R. (Wolfgang), Heyndrickx, G.R. (Guy), Emanuelsson, H.U. (Hakan), Marco, J. (Jean), Legrand, V.M.G. (Victor), Materne, P.H. (Phillipe), Belardi, J.A. (Jorge), Sigwart, U. (Ulrich), Colombo, A. (Antonio), Goy, J-J. (Jean-Jacques), Heuvel, P. van den, Delcan, J., Morel, M-A.M. (Marie-Angèle), Serruys, P.W.J.C. (Patrick), Jaegere, P.P.T. (Peter) de, Kiemeneij, F. (Ferdinand), Miguel, C.M. (Carlos), Rutsch, W.R. (Wolfgang), Heyndrickx, G.R. (Guy), Emanuelsson, H.U. (Hakan), Marco, J. (Jean), Legrand, V.M.G. (Victor), Materne, P.H. (Phillipe), Belardi, J.A. (Jorge), Sigwart, U. (Ulrich), Colombo, A. (Antonio), Goy, J-J. (Jean-Jacques), Heuvel, P. van den, Delcan, J., and Morel, M-A.M. (Marie-Angèle)
- Abstract
BACKGROUND. Balloon-expandable coronary-artery stents were developed to prevent coronary restenosis after coronary angioplasty. These devices hold coronary vessels open at sites that have been dilated. However, it is unknown whether stenting improves long-term angiographic and clinical outcomes as compared with standard balloon angioplasty. METHODS. A total of 520 patients with stable angina and a single coronary-artery lesion were randomly assigned to either stent implantation (262 patients) or standard balloon angioplasty (258 patients). The primary clinical end points were death, the occurrence of a cerebrovascular accident, myocardial infarction, the need for coronary-artery bypass surgery, or a second percutaneous intervention involving the previously treated lesion, either at the time of the initial procedure or during the subsequent seven months. The primary angiographic end point was the minimal luminal diameter at follow-up, as determined by quantitative coronary angiography. RESULTS. After exclusions, 52 patients in the stent group (20 percent) and 76 patients in the angioplasty group (30 percent) reached a primary clinical end point (relative risk, 0.68; 95 percent confidence interval, 0.50 to 0.92; P = 0.02). The difference in clinical-event rates was explained mainly by a reduced need for a second coronary angioplasty in the stent group (relative risk, 0.58; 95 percent confidence interval, 0.40 to 0.85; P = 0.005). The mean (+/- SD) minimal luminal diameters immediately after the procedure were 2.48 +/- 0.39 mm in the stent group and 2.05 +/- 0.33 mm in the angioplasty group; at follow-up, the diameters were 1.82 +/- 0.64 mm in the stent group and 1.73 +/- 0.55 mm in the angioplasty group (P = 0.09), which correspond to rates of restenosis (diameter of stenosis, > or = 50 percent) of 22 and 32 percent, respectively (P = 0.02). Peripheral vascular complications necessitating surgery, blood transfusion, or both were more frequent after stenting than after
- Published
- 1994
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.